Mar 19, 2026 04:05PM
Mar 12, 2026 08:44AM
Mar 12, 2026 08:35AM
Jan 8, 2026 12:08PM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Aug 12, 2025 04:05PM SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 15, 2025 07:45AM
Jul 15, 2025 07:45AM
May 15, 2025 08:45AM
May 15, 2025 08:45AM
May 13, 2025 04:05PM
Apr 8, 2025 08:45AM
Apr 8, 2025 08:45AM SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
Mar 20, 2025 04:05PM
Jan 8, 2025 08:20AM
Jan 8, 2025 08:20AM
Nov 13, 2024 04:15PM
Oct 15, 2024 08:45AM
Oct 15, 2024 08:45AM
Aug 13, 2024 04:10PM SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 6, 2024 08:45AM
Aug 6, 2024 08:45AM
Jul 16, 2024 09:05AM
Jul 16, 2024 09:05AM
Jul 8, 2024 08:46AM
Jul 8, 2024 08:45AM
Jun 24, 2024 09:05AM SELLAS Life Sciences (SLS) Granted FDA Rare Pediatric Disease Designation for SLS009
Jun 24, 2024 09:05AM
Jun 18, 2024 08:45AM
Jun 17, 2024 09:45AM
May 1, 2024 08:36AM
May 1, 2024 08:35AM
Mar 28, 2024 04:05PM
Mar 28, 2024 07:00AM GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating
Jan 11, 2024 06:00AM
Jan 9, 2024 08:33AM
Jan 9, 2024 08:30AM
Jan 3, 2024 07:31AM
Jan 3, 2024 07:30AM
Dec 21, 2023 08:15AM
Dec 21, 2023 08:15AM SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
Dec 20, 2023 03:48PM
Dec 14, 2023 08:30AM
Nov 29, 2023 08:45AM
Nov 13, 2023 08:50AM
Nov 13, 2023 08:50AM
Nov 9, 2023 04:04PM
Oct 30, 2023 09:03AM SELLAS Life Sciences (SLS) Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
Oct 30, 2023 09:03AM

322,900 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All